Are Mammograms Bad for You? The Risks and Downsides

Mammograms save lives, but they come with a real set of downsides that most women never hear about in detail. The most common harms include false-positive results that trigger unnecessary biopsies and anxiety, overdiagnosis of cancers that would never have caused symptoms, a small radiation exposure that accumulates over decades, and the physical pain of breast compression. None of these make mammography “bad” in the way that, say, an unsafe drug is bad, but they do mean that screening is a tradeoff, and the balance shifts depending on your age, breast density, and personal risk.

False Positives Are Surprisingly Common

The single most frequent downside of mammography screening is getting called back for something that turns out not to be cancer. If you screen annually starting at age 40, the chance of receiving at least one false-positive recall over ten years is roughly 50 to 61 percent, depending on the study and the imaging technology used. With biennial screening, that probability drops to around 36 to 42 percent, which is better but still means more than a third of women will experience it.¹ A large study using digital breast tomosynthesis, which is the newer 3D mammography, found a somewhat lower ten-year false-positive recall rate of about 50 percent for annual screening compared with 56 percent for standard digital mammography, an improvement but still high.²

A false-positive recall does not always mean a biopsy. Many women are simply called back for additional imaging and then cleared. But an estimated 7 to 19 percent of women who do not have cancer will undergo at least one biopsy over a decade of screening.³ That adds up fast across the population.

The Psychological Toll of a False Alarm

Getting told “we see something, come back for more tests” is frightening, even when the follow-up shows nothing wrong. Research consistently shows a moderate but real increase in anxiety, worry, and psychological distress after a false-positive mammogram. In one study, women with false-positive results scored higher on anxiety measures in the short term compared to women whose results were normal, though the difference largely faded by one year.⁴ Other research paints a longer shadow: women who reported a prior false positive were more likely to feel sad, restless, and worthless, and were more likely to have seen a mental health professional in the previous year.⁵

Reviews of the psychological literature have found that about one in five women report a negative effect on their daily functioning after an abnormal mammogram result, and some studies detected significant anxiety persisting 18 months later.⁶ People vary a lot in how they respond, and many women shake off a false alarm quickly. But for a meaningful minority, the experience lingers.

What False Positives Cost You Financially

Beyond the emotional burden, false positives generate real medical bills. The median cost of breast-related care in the year following a false-positive mammogram was about $338 when only additional imaging was needed, but jumped to roughly $2,192 when a biopsy was involved.⁷ At a national level, one analysis estimated that false-positive mammograms and overdiagnosed breast cancers together cost the U.S. health system roughly $4 billion per year, with an average per-case expenditure of $852 for each false-positive mammogram.⁸ Even with insurance, out-of-pocket costs from follow-up imaging and biopsies can be significant, especially for women who are underinsured.

Overdiagnosis and Treatments You May Not Have Needed

Overdiagnosis is the most conceptually troubling harm of mammography. It refers to detecting a cancer that is real on a pathology slide but would never have grown, spread, or caused symptoms during the woman’s lifetime. Because we cannot yet reliably distinguish slow-growing or dormant tumors from aggressive ones at the time of diagnosis, nearly all detected cancers get treated with surgery, radiation, or chemotherapy. That means some women undergo serious treatment for a disease that would never have hurt them.

How common is this? Estimates vary widely depending on the methodology, which is part of what makes the issue so contentious. A 2023 meta-analysis of studies on women aged 40 and older estimated an overdiagnosis rate of about 13 percent.⁹ But individual studies have produced numbers ranging from low single digits to over 30 percent, and the heterogeneity among them is enormous. What everyone agrees on is that overdiagnosis is a real phenomenon and that it rises with age: women who begin screening later in life, closer to 70, face higher overdiagnosis rates because competing causes of death become more likely to arrive before a slow-growing tumor would.¹⁰

The practical implication is subtle but important. The greatest harm from overdiagnosis is overtreatment, and some researchers argue the solution is not to screen less but to develop better tools for deciding which detected cancers actually need aggressive treatment.¹¹ Active surveillance, where a detected tumor is monitored rather than immediately treated, is being studied for low-risk breast cancers just as it is used for certain low-risk prostate cancers. Until those tools mature, overdiagnosis remains baked into the screening process.

Radiation Exposure From Repeated Mammograms

Mammography uses low-dose X-rays, and any ionizing radiation carries a tiny risk of causing the very disease it is meant to detect. The dose from a standard two-view mammogram is small, roughly equivalent to a few weeks of natural background radiation. But the doses accumulate over years of screening, and modeling studies have estimated what that cumulative exposure means in concrete terms.

One widely cited modeling study projected that annual screening of 100,000 women from age 40 to 74 would induce about 125 breast cancers leading to 16 deaths, set against 968 breast cancer deaths averted by early detection. That is roughly a 60-to-1 benefit-to-risk ratio for deaths averted versus deaths caused.¹² Switching to biennial screening starting at age 50 reduced the radiation-induced cancer risk about fivefold. Women with larger breasts who require additional views for complete imaging had a higher projected risk: about 266 radiation-induced cancers per 100,000 women compared with 113 for women with smaller or average-sized breasts.¹² A separate modeling study using slightly different assumptions arrived at a similar order of magnitude: 86 induced cancers and 11 deaths per 100,000 women screened annually from 40 to 55 and biennially thereafter.¹³

For women with BRCA1 or BRCA2 mutations, the risk picture is different. A retrospective cohort study found that any exposure to diagnostic radiation before age 30 was associated with a roughly doubled breast cancer risk in these carriers.¹⁴ This is one reason that MRI, which uses no ionizing radiation, is the preferred screening tool for very-high-risk young women rather than mammography.

The Pain Factor

Mammography requires compressing the breast between two plates, and for many women, it hurts. In a large survey, the average pain score during compression was about 3.3 on a 10-point scale, and roughly 72 percent of women rated their overall pain at 4 or below.¹⁵ That means for most women the experience is unpleasant but tolerable. Still, about 94 percent said they were likely to return for another mammogram, so pain alone does not stop the vast majority from screening.

But it does stop some. A systematic review found that among women who failed to return for their next scheduled screening mammogram, 25 to 46 percent cited pain as a reason. Women who experienced pain at a previous mammogram were about a third more likely to skip their next appointment.¹⁶ That is an indirect harm of mammography worth recognizing: if the experience is painful enough to drive women away from future screening, the discomfort may cost more than it saves in the long run.

What Mammograms Miss

Mammography is not a perfect detector. It misses some cancers entirely, and the most important factor governing its sensitivity is breast density. Dense breast tissue, which contains more fibroglandular tissue relative to fatty tissue, appears white on a mammogram, and so do tumors. The overlap can mask cancers. Women with dense breasts have screening sensitivity estimated at about 78 percent compared with 88 percent for women with non-dense breasts.¹⁷ In other words, mammography misses roughly one in five cancers in women with dense breasts.¹⁸

Cancers that appear between scheduled screenings, called interval cancers, are another measure of what mammography misses. An audit of 167 interval cancers found that about 26 percent were classified as “false negatives,” meaning they were visible in retrospect on the previous screening mammogram but were not flagged at the time.¹⁹ This does not mean the radiologist was negligent; many of these are subtle findings that are extremely difficult to spot in real time. But it does mean mammography has a meaningful miss rate, and women should not treat a clean mammogram as an absolute guarantee.

Supplemental Screening for Dense Breasts Creates Its Own Tradeoffs

Many states now require that women be notified if they have dense breasts, and some physicians recommend supplemental screening with ultrasound or MRI. These additional tests do catch cancers that mammography misses, but they also generate more false positives. One modeling study estimated that supplemental ultrasound screening after a negative mammogram for women aged 50 to 74 with dense breasts averted an additional 0.36 breast cancer deaths per 1,000 women screened, but resulted in 354 biopsy recommendations from false-positive ultrasound results per 1,000 women.²⁰ That is a lot of unnecessary biopsies for a modest mortality benefit. Newer evidence from the ASTOUND trial has shown lower false-positive rates when ultrasound is combined with tomosynthesis, suggesting the tradeoff may improve as protocols are refined.²¹

How Age and Frequency Shift the Risk-Benefit Balance

The harms of mammography screening are relatively constant at any age: false positives, overdiagnosis, radiation, and pain all occur regardless of whether you are 42 or 62. But the benefits increase with age because breast cancer becomes more common in older women, meaning each mammogram is more likely to find something real. This is why the risk-benefit equation looks different for a 40-year-old than for a 55-year-old.

One estimate found that roughly 2,500 women in their forties would need to be screened every one to two years for a decade to prevent one breast cancer death, requiring between 12,500 and 25,000 individual mammographic examinations per death prevented. For women who began screening at 50, about 270 women screened biennially for 20 years, or approximately 2,700 examinations, would prevent one death.²² That nearly tenfold difference in “number needed to screen” explains why guidelines have historically been more cautious about recommending routine screening for women in their forties.

Screening frequency matters too. Annual screening catches more cancers but also roughly doubles the cumulative false-positive rate compared with biennial screening. Every major guideline group agrees that mammography is the standard for average-risk women, but they diverge on when to start and how often to screen, with recommendations ranging from annual at 40 to biennial starting at 50.²³ These are not disagreements about the science of breast cancer; they are disagreements about how to weigh known benefits against known harms.

Most Women Hear About Benefits but Not Harms

One reason the question “are mammograms bad for you?” feels taboo is that public messaging about mammography has overwhelmingly emphasized the life-saving side. A national survey found that women were far more aware of mammography’s benefits than its harms, and women who had recently been screened were even more likely to rate those benefits as important. The researchers attributed this in part to a lack of balanced information from physicians, public health campaigns, and advocacy organizations.²⁴ This creates a climate where asking about downsides can feel like you are questioning something sacred, even though every screening test in medicine carries tradeoffs that patients have a right to understand.

Qualitative research with women themselves has shown that many report hearing inconsistent recommendations from their doctors and mixed messages from media reports.²⁵ The confusion is understandable: when one professional organization says “start at 40, screen yearly” and another says “start at 50, screen every two years,” the public hears uncertainty where the reality is a genuine values-based disagreement about acceptable levels of harm.

How Malpractice Fears Inflate Recall Rates

One underappreciated driver of false positives in the United States is the legal environment. Breast cancer is the single most common cause of medical malpractice claims in radiology, and radiologists know it. A study of community radiologists found that U.S. radiologists are extremely concerned about malpractice and that this concern directly affects their recall rates and biopsy recommendations.²⁶ In practical terms, a radiologist who fears being sued for missing a cancer has a strong incentive to call back any image that looks even slightly ambiguous. This is rational self-protection on the radiologist’s part, but it means American women experience higher false-positive rates than women in countries with lower litigation risk. A meta-analysis of tomosynthesis studies found that recall rates dropped with the new technology in U.S. studies but not in European ones, partly because European recall rates were already lower to begin with.²⁷

Risk-Stratified Screening as an Emerging Alternative

The blunt approach of screening every woman the same way regardless of her individual risk is increasingly being questioned. Risk-stratified screening uses factors like genetics, family history, breast density, and sometimes polygenic risk scores to sort women into different risk tiers and then screen them accordingly: more frequently and with more modalities for high-risk women, less frequently or starting later for low-risk women. Early results from trials testing this approach are encouraging. One retrospective evaluation found that risk-based screening produced a negligible difference in overdiagnosis compared with clinical examination, while achieving an 8 percent reduction in later-stage cancers.²⁸

A randomized trial of risk-stratified screening found that the approach was feasible and that women assigned to less-frequent screening based on their low risk accepted the change without significant psychological distress.²⁹ The appeal is straightforward: if you could give high-risk women more screening while sparing low-risk women the false positives, overdiagnosis, and anxiety of screening they are unlikely to benefit from, you would reduce the total harms of mammography without sacrificing the mortality reduction. These programs are still largely in the research phase, but they represent the most promising path toward addressing mammography’s downsides structurally rather than simply asking women to accept them.